The Deal Register
Database › M&A › LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND…

M&A

LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M…

Lane
M&A
Announced
23 Dec 2025
Province
Quebec
Industry
Healthcare & life sciences
Status
Announced
What the filing says
LSL PHARMA GROUP INC. (TSXV: LSL ) (The " Corporation " or " LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce that it has completed the acquisition (the " Acquisition ") from Juno Pharmaceuticals LP (the " Seller ") of all of the outstanding shares of Juno OTC Inc. (" Juno OTC "), a Toronto based wholly owned subsidiary of the Seller, for a total purchase price of $5 million (the " Purchase Price ").
Terms stated
conversion price, interest rate, maturity date, price per security
Releases (3)
  • 17 Dec 2025 — LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
  • 23 Dec 2025 — LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
  • 23 Dec 2025 — LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
Source

The terms are in the subscriber edition

This transaction carries 5 stated terms, with the value, unit and basis of each and the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe